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INTRODUCING THE PROGESTERONE 
CONTRACEPTIVE VAGINAL RING  
IN SUB-SAHARAN AFRICA 
 
Research supports the introduction of the 
Progesterone Vaginal Ring (PVR), a user-controlled 
method that helps breastfeeding women safely 
space or delay their next pregnancy. 
 
In sub-Saharan Africa, particularly across Kenya, Nigeria, and 
Senegal, ongoing efforts are helping expand access to contraceptive 
methods for breastfeeding women. These efforts begin with basic 
research and development to bring innovations in family planning 
from bench to bedside, and continue with a deepening 
understanding of the intricacies of product introduction in 
underserved communities.  
For the first six months after childbirth, exclusive breastfeeding 
provides effective contraception, but many women do not or are 
unable to breastfeed exclusively. Once a woman stops 
breastfeeding, begins adding other foods or liquids to her infant’s 
diet, or starts menstruating again, she is at risk of becoming 
pregnant.  
To bridge the gap between the demand for innovation and access to 
novel contraceptive options for breastfeeding women, the 
Population Council and its partners conducted three distinct 
Willingness to Pay research initiatives to estimate the effect of price 
on demand for the Progesterone Vaginal Ring (PVR) in sub-Saharan 
Africa, where unmet need is outpacing the ability to provide timely, 
cost-effective access to new methods.  
Additionally, changes in the resource landscape have prompted 
governments to explore “Total Market” solutions. The Total Market 
Approach is defined as a coordinated approach that serves all 
clients in a country—from those requiring free or highly subsidized 
services to those who are willing and able to pay—to maximize 
access, equity, and sustainability and to direct scarce resources to 
sectors and users where need is not met. Using this as a guiding 
design principle, this research provides new insights on the amount 
consumers are willing to pay for the PVR from various service 
sectors—public, private nonprofit, and private commercial (Evidence 
Project 2014; Obare et al. 2014). 
 
UNDERSTANDING THE PVR: 
WHAT IT IS, HOW IT WORKS 
The PVR releases a continuous 
low dose of the natural hormone 
progesterone, which reinforces 
the inhibitory effect of breast-
feeding on ovulation, delays the 
return of the menstrual cycle, 
and therefore prevents 
pregnancy without affecting the 
quality of breast milk.  
A woman can begin using the 
PVR as early as six weeks after 
birth if her menstrual cycle has 
not yet returned. A single ring can 
be used for three months and a 
woman can replace it with a new 
one up until her child’s first 
birthday.  
In clinical trials, the PVR was 
98.5% effective in preventing 
pregnancy when used correctly.  
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RESEARCH AND KEY FINDINGS 
Within each country, the Council and partners sought to:  
 Evaluate the willingness to pay for the PVR 
among women at health facilities in the public, 
private nonprofit, and private commercial sectors. 
 Assess providers’ willingness across public, 
private nonprofit, and private commercial sectors 
to counsel and offer the PVR to women.  
 Understand the willingness to procure the PVR 
among suppliers (e.g., governments, donors). 
Stakeholders noted consistent reasons supporting the 
willingness to pay, including provider recommendations of 
the PVR, wanting/liking the method, desire to prevent 
unintended pregnancy, and heightened interest in helping 
broaden access to the PVR for women.  
 
Overall, although cost plays an important role in 
regulating consumer demand, women and their health 
care providers indicated that the desire to avoid 
unintended pregnancy and the need for access to modern 
contraception outweighed cost barriers as critical 
components that influence family planning decision-
making. Provider interest in a woman-controlled method 
that requires minimal provider counseling to ease the 
burden on their time and the possibility of distribution 
through community health workers was evident. 
 
Across all three countries, most participants (up to 85% of 
women, 95% of procurers, and 100% of providers) 
expressed interest in the one-year Nestorone®/Ethinyl 
Estradiol contraceptive vaginal ring (CVR) and even 
expressed a willingness to pay higher prices for the ring. 
WILLINGNESS TO PAY: KENYA 
The public sector remains the primary source of sexual 
and reproductive health care financing in Kenya, but 
funding shortages have prompted the exploration of new 
financing models to help meet the contraceptive needs of 
women and their families. So the private sector remains a 
key option for contraceptive security. As Kenya is among 
the most vibrant economies in East Africa (with 4.9% 
economic growth reported in the first quarter of 2015), 
it’s even more important to equip and empower women 
with a range of family planning services and resources to 
help maintain their health and support their contributions 
to economic growth.   
While Kenya’s total fertility rate (TFR) has declined 
significantly since the mid-1970s, the current rate 
remains at roughly 3.9 births per woman (3.1 and 4.5 
births in urban and rural regions, respectively). And, just 
more than half of married women (58%) are using a 
contraceptive method, although contraceptive 
prevalence reportedly increases substantially with 
higher education rates. Despite the progress made in 
contraceptive use, many women are still left behind—
especially those who need access to a contraceptive in 
the first 12 months postpartum.  
In this study, willingness to pay was evaluated in 
Nairobi County, as it has the highest concentration 
of urban, educated women. And, because family 
planning counseling is offered free of charge, the 
study sought to understand whether women, 
providers, and procurers would be receptive to 
paying for and obtaining the PVR, especially given 
the global effort to move economies toward a Total 
Market Approach. 
Key findings from the Kenya WTP study (Liambila et al. 
2015) include:  
 Women reported that they would be willing to 
pay for the PVR if it was available to them.  
 A majority who obtain services through the 
private commercial sector spend, on average, 
between 50 cents and US$2 (50–199 Kenya 
shillings [KES]) each month on family planning—
suggesting a market exists for the introduction 
of new products via the private sector. 
 Most women surveyed would pay a price 
equal to a three-month supply of progestin-
only pills, plus a 10% increase. Women who 
rely on the public sector for the provision of 
family planning services were more sensitive 
to marginal price increases compared with 
those interviewed at private-sector facilities.  
 A majority noted that they would look for 
affordable alternatives (52%) and go to 
places where the PVR might be provided free 
of charge (27%) if the selling price of the PVR 
is too high for them.  
 Providers highlighted the value of the PVR as 
an important addition to the contraceptive 
method mix, particularly in light of frequent 
prolonged stock-outs of other methods—
including oral contraceptives.  
 
Interestingly, procurers expressed willingness to 
make the PVR available through their networks and 
indicated willingness to purchase at a higher cost 
than what women reported. 
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Taken together, these findings indicate a high level of 
interest in seeking, obtaining, and providing the PVR 
across a diverse range of stakeholders in Kenya, and 
underscore the value that social marketing 
organizations and commercial groups can play in 
helping ease the burden on public health 
expenditures.  
By leveraging Kenya’s growing economy and 
supporting cross-collaboration through the provision 
of family planning services, these findings accentuate 
a positive outlook for postpartum breastfeeding 
women who need access to novel, woman-controlled, 
discreet methods without placing a burden on 
already-stretched health care resources. 
WILLINGNESS TO PAY: NIGERIA 
In Nigeria, family planning financing was entirely donor-
driven until 2011 when the Federal Government of 
Nigeria committed to providing US$3 million annually 
from 2011 to 2015 for procurement of contraceptives for 
the public sector. Following the London summit in 2012, 
the Nigerian government made a further pledge of 
providing an additional US$8.3 million. 
Contraceptive services and commodities are 
available free of charge at public health facilities in 
Nigeria; however, public facilities have frequent 
stock-outs and therefore the private sector accounts 
for more than 60% of provision across rural and 
urban settings.  
Over the last two decades, Nigeria’s contraceptive 
prevalence rate (CPR) for modern contraception has 
remained steadily at 10%, representing one of the 
lowest rates in sub-Saharan Africa. However, 
Nigeria’s Federal Ministry of Health has set an 
ambitious new target of raising the CPR to more than 
35% by the year 2018. One method identified to help 
achieve this goal is addressing the needs of 
postpartum women, where the need is 65% (as 
opposed to just above 15% for nonpostpartum 
women). Further, procurement, pricing, and quality 
assurance systems are particularly robust in Nigeria.  
In the country, providers across all three sectors indicated 
the importance of including the PVR in the method mix. 
Their responses highlighted the importance of educating 
potential providers to ensure their successful integration 
when eventually registered. 
Key findings from the Nigeria analysis (Ishaku et al. 
2015) include:  
• Women, providers, and procurers 
unanimously expressed support for the PVR 
suggesting that the method could represent a 
welcome development and add value to the 
family planning landscape. 
 Women were willing to pay for the PVR 
regardless of the sector at a price of US$1.70 
(300 Naira [N]); and, in the private 
commercial and nonprofit sectors, a 
significant portion of women noted 
willingness to purchase the PVR at higher 
prices. 
 Stakeholders also expressed interest and 
support/willingness to try the one-year 
investigational CVR—a ring that, if approved 
by regulatory authorities, could potentially be 
used for up to one full year. 
WILLINGNESS TO PAY: SENEGAL 
With a population estimated at 13 million in 2014, 
Senegal continues to face a high population growth 
rate (approximately 2.5%). Consequently, this 
growth rate contributes to a predominantly young 
population (more than 50% under 18 years of age), 
which should lead to a higher fertility rate (births 
per 1,000 women of reproductive age) in the next 
decade. According to 2013 estimates, Senegal’s 
total fertility rate is about 5.3 children per woman.  
The desire for large families in Senegal comes from 
cultural beliefs that children bring life into the 
household and are an investment. High fertility  
is also related to the low use of modern 
contraception. Following its engagement in the 
Ouagadougou Declaration, the Ministry of Health 
launched a voluntary National Action Plan for 
Family Planning in 2012. The objective is to 
increase the Contraceptive Prevalence Rate from 
12% to 27% by 2015 and 45% in 2020.  
Senegal’s Dakar region—which boasts the highest 
population density—maintains an unmet need for 
family planning of 32%, which has remained 
constant despite a higher modern CPR of 21%, 
due in part to frequent stock-outs. According to 
DHS records from 2010–11, 60% of women who 
gave birth in the two years prior to the survey 
reported unmet need. Among postpartum women, 
66% who were breastfeeding reported unmet 
need versus 40% for those not breastfeeding. 
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Key findings from the Senegal analysis (Mané et al. 
2015) include:  
 Women in the public and private nonprofit 
sectors were willing to pay US$1–$2 (500–
1,000 FCFA) for the PVR. And, among 
potential users who learned about the PVR for 
the first time, more than 70% expressed 
interest in using it—and this “willingness to try” 
highlights the high unmet need and 
opportunity for the PVR in creating value for 
Senegalese women. 
 Of women interested, more than 85% reported 
willingness to pay, even if the price rose, to 
avoid unintended pregnancy.  
 Across all sectors, health care providers 
reported willingness to offer the PVR—and 
supported its inclusion in the country’s 
national family planning program. Providers 
also supported a price as high as US$2 per 
ring (1,000 FCFA) in the public and private 
nonprofit sectors, with those in the 
commercial private sector willing to pay more.  
 Procurers were unanimously supportive of the 
PVR and recommended prices as high as 
US$4.  
CONCLUSIONS AND KEY LEARNINGS 
Product introduction strategies demand rigorous 
market research and often rely on hypothetical 
approaches to gauge demand, provider interest, and 
procurers’ ability and willingness to make new 
contraceptive methods available to the women who 
need them most. In addition to considering what price 
stakeholders are willing to pay, it is essential to weigh 
price against a stream of potential benefits—the 
potential health outcomes, improvements and 
efficiencies in the health system, and individual and 
societal health and economic gains. Furthermore, a 
pricing model defines the prices paid and benefits 
accrued to different stakeholders.  
Clinical trial results demonstrate that the PVR is safe for 
both mothers and their babies, in addition to being 98.5% 
effective when used correctly. Research also indicates 
that women may experience other health benefits from 
breastfeeding, such as reduced risk of ovarian and breast 
cancer (Sivin et al. 1995; Carr et al. 2015). As such, the 
PVR represents an important addition to the 
contraceptive method mix and product landscape for 
postpartum women in developing countries where 
resources are scarce. 
 
With adequate planning for the introduction of a 
new contraceptive product, the health care sector 
can ensure that women are able to access the 
right product, in the right place, at the right time.  
Sustaining an effective Total Market Approach is 
key to increasing family planning access and use, 
as well as ensuring continuation of services across 
public and private sectors. Central to this 
approach is that providers in the public and 
private sectors leverage their comparative 
advantages to reach different types of clients with 
appropriate products and services. 
The PVR contributes to a Total Market Approach 
by reaching new clients who might otherwise be 
overlooked due to resource constraints, creating 
the opportunity to improve equitable access. 
In addition to the PVR, the Population Council and 
its partners are continuing development of a one-
year, long-acting, reversible contraceptive vaginal 
ring (CVR) containing two hormones that, if 
approved by regulatory agencies, could be used  
by nonbreastfeeding women. In each study, 
participants were asked if they would be 
interested in this method as an alternative to 
other long-acting methods (e.g., IUDs), because 
the CVR is also designed to be woman-controlled 
and would offer a comparable level of discretion.  
Women across all three countries expressed 
interest and willingness to pay for this product.    
Willingness to pay and the price paid by different 
stakeholders are important considerations in  
the initial stages of introduction of a new 
contraceptive. As the market matures for the 
contraceptive, the potential for price reductions 
emerges. Efficiencies in manufacturing and 
distribution to meet increased demand can lower 
prices, as can the entry of new manufacturers. 
With the overall contraceptive market poised to 
grow in the next two decades to meet the needs of 
a growing population, the dynamics of supply and 
demand will significantly alter the initial price 
offering. 
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